This useful center offers information on knee osteoarthritis treatment and management including patient handouts, multimedia and featured articles.

Multimedia

Video

A Helpful Guide to Managing OA Knee Pain

Get tips and information about Synvisc-One and OA knee pain from family practitioner and sports medicine specialist, Joseph J. Ruane, DO, to help you better help your patients find relief.

Clinical Summaries

Learn how Synvisc-One can help provide your patients up to 6 months of osteoarthritis pain relief with a single injection.*

 

Important Safety Information

SYNVISC and Synvisc-One are contraindicated in patients with known hypersensitivity to hyaluronan products or patients with infections in or around the target knee. Hypersensitivity reactions including anaphylactic reaction, anaphylactoid reaction...

View more.

Downloads for Your Patients

Patient Handouts

Download helpful information to share with your knee OA patients.

Synvisc-One FAQs

Get Answers to Your Questions about Synvisc-One

How Synvisc-One is helping to relieve osteoarthritis knee pain.

 

View the Latest from ADVANCE

 

Search Jobs

Go
 
 
 
 

*The safety and effectiveness of Synvisc-One was studied against saline control over 26 weeks in a double-blinded, randomized clinical trial in patients with OA knee pain

Indication

SYNVISC® (hylan G-F 20) and Synvisc-One® (hylan G-F 20) are indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative nonpharmacologic therapy and simple analgesics, e.g., acetaminophen.

Important Safety Information

SYNVISC and Synvisc-One are contraindicated in patients with known hypersensitivity to hyaluronan products or patients with infections in or around the target knee. Hypersensitivity reactions including anaphylactic reaction, anaphylactoid reaction, anaphylactic shock and angioedema have been reported for both SYNVISC and Synvisc-One.

Do not concomitantly use disinfectants containing quaternary ammonium salts for skin preparation because hyaluronan can precipitate in their presence. Do not inject SYNVISC or Synvisc-One extraarticularly, into the synovial tissues, into the fat pad or joint capsule, or intravascularly.

The safety and efficacy of Synvisc-One in locations other than the knee, or for conditions other than osteoarthritis, or in combination with other intra-articular injectables, or in severely inflamed knee joints have not been established. Use caution when injecting SYNVISC or Synvisc-One in patients allergic to avian proteins, feathers, or egg products; who have evidence of lymphatic or venous stasis in the leg to be treated; or who have severe inflammation in the knee to be treated. Remove any synovial fluid or effusion before injecting SYNVISC or Synvisc-One. Strict adherence to aseptic technique must be followed to avoid joint infection. The safety and effectiveness of SYNVISC and Synvisc-One have not been established in children (≤21years old) or in pregnant or lactating women. Patients should be advised to avoid strenuous or prolonged weight-bearing activities for approximately 48 hours after treatment.

For SYNVISC

In clinical trials, the most commonly reported adverse events were transient pain, swelling, and or joint effusion in the injected knee. The following reported adverse events are among those that may occur in association with intra-articular injections, including Synvisc: arthralgia, joint stiffness, joint effusion, joint swelling, joint warmth, injection site pain, arthritis, arthropathy, and gait disturbance.

Full Prescribing Information for SYNVISC

For Synvisc-One

The most commonly reported adverse events were arthralgia, arthritis, arthropathy, injection site pain, and joint effusion. The following reported adverse events are among those that may occur in association with intra-articular injections, including Synvisc-One: arthralgia, joint stiffness, joint effusion, joint swelling, joint warmth, injection site pain, arthritis, arthropathy, and gait disturbance.

Full Prescribing Information for Synvisc-One

© 2015 Genzyme Corporation, a Sanofi Company. All rights reserved. Synvisc-One, SYNVISC and

GENZYME are registered trademarks of Genzyme Corporation. US.SYN.15.10.002

Back to Top

© 2017 Merion Matters

660 American Avenue Suite 300, King of Prussia PA 19406

1-484-804-4888